home2022-08-08T08:13:43+02:00

biomarkers for more stability in life

our purpose:
precision
medicine

discovery_and_validation_of_microRNA_biomarkers

TAmiRNA is a biotech company specialized in the discovery and validation of microRNA biomarkers. Our mission is to provide validated diagnostic solutions to patients with serious aging-related illnesses. We aim to improve and prolong patient stability, health and quality of life with increasing age.

TAmiRNA - stability for live

our technology:
microRNA
signatures

mircoRNA_signatures

We are specialized in biomarker development using blood-circulating microRNAs – evolutionary conserved regulators of gene expression and cell/tissue function. We develop diagnostic algorithms (“signatures”) based on the logic combination of microRNA levels and clinical parameters.

TAmiRNA - stability for live

our focus:
age-associated
diseases

age_associated_diseases

TAmiRNA is actively involved in R&D projects in osteoporosis (OP), cardio-vascular disease (CVD), liver disease and aging. OP and CVD are multifactorial illnesses. Using microRNA signatures we aim to decode the contributing disease factors on a personalized level, and to use this knowledge for better diagnosis.

TAmiRNA - stability for live

biomarkers for more stability in life

our purpose:
precision
medicine

discovery_and_validation_of_microRNA_biomarkers

TamiRNA is a biotech company specialized in the discovery and validation of microRNA biomarkers. Our mission is to provide validated diagnostic solutions to patients with serious aging-related illnesses. We aim to improve and prolong patient stability, health and quality of life with increasing age.

our technology:
microRNA
signatures

mircoRNA_signatures

We are specialized in biomarker development using blood-circulating microRNAs – evolutionary conserved regulators of gene expression and cell/tissue function. We develop diagnostic algorithms (“signatures”) based on the logic combination of microRNA levels and clinical parameters.

our focus:
age-associated
diseases

TAmiRNA is actively involved in R&D projects in osteoporosis (OP), cardio-vascular disease (CVD), liver disease and aging. OP and CVD are multifactorial illnesses. Using microRNA signatures we aim to decode the contributing disease factors on a personalized level, and to use this knowledge for better diagnosis.

our products

TAmiRNA - stability for live
TAmiRNA - stability for live
TAmiRNA - stability for live
SARS-CoV-2 Antibody Test

our products

TAmiRNA - stability for live
TAmiRNA - stability for live
TAmiRNA - stability for live

our services

microRNA services

services

Serum, plasma, urine, saliva, exosomes, cells, and tissues … We provide solutions for your biomarker discovery and validation needs in any biological matrix.

TAmiRNA - the power of microRNA biomarkers

Kit services

Send us your samples to obtain results for osteomiR™, thrombomiR® or toxomiR® biomarkers by taking advantage of our in-house services.

TAmiRNA - the power of microRNA biomarkers

SARS-CoV-2 PCR Test Service

SARS_COVID_PCR_Logo

TAmiRNA is offering a test service for direct detection of SARS-CoV-2 viral RNA in biological samples.

TAmiRNA - the power of microRNA biomarkers
Click_here_for_your_personalized_microRNA_service_offer

our services

microRNA services

services

Serum, plasma, urine, saliva, exosomes, cells, and tissues … We provide solutions for your biomarker discovery and validation needs.

TAmiRNA - the power of microRNA biomarkers

One-Stop-Shop

Obtain results for osteomiR, thrombomiR,and toxomiR biomarkers in your samples by taking advantage of our inhouseservices.

TAmiRNA - the power of microRNA biomarkers

SARS-CoV-2 PCR Test Service

SARS_COVID_PCR_Logo

TAmiRNA is offering a test service for direct detection of SARS-CoV-2 viral RNA in biological samples.

TAmiRNA - the power of microRNA biomarkers
TAmiRNA - stability for live

latest news

We are proud to announce our ISO 13485:2016 certification

By |January 31st, 2023|Categories: biomarkers, ISO 13485, microRNA, quality, smallRNA|Tags: , , , , , |

Today we announce that TAmiRNA has received ISO 13485:2016 certification for its Medical Device and Quality Management System after successfully completing the audit through Germany-based notified body MDC. This [...]

Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects

By |January 30th, 2023|Categories: biomarkers, diagnose disease, extracellular vesicle, microRNA, platelet-associated miRNAs, smallRNA, thrombomiR, treatment monitoring|Tags: , , , , , , , , |

We want to draw your attention to our most recent publication where we investigated platelet-enriched miRNAs (thrombomiRs) as suitable candidates for monitoring antiplatelet therapy. The study provides evidence that [...]

Biogenity Joins Forces with TAmiRNA

By |January 17th, 2023|Categories: biomarkers, diagnose disease, microRNA, NGS, smallRNA, treatment monitoring|Tags: , , , , , , , |

The collaboration between Biogenity and TAmiRNA is a big step towards further enabling our clients to identify new biomarkers that can be used to diagnose disease, monitor treatment response, [...]

Comments Off on Biogenity Joins Forces with TAmiRNA

We are proud to announce our ISO 13485:2016 certification

By |January 31st, 2023|Categories: biomarkers, ISO 13485, microRNA, quality, smallRNA|Tags: , , , , , |

Today we announce that TAmiRNA has received ISO 13485:2016 certification for its Medical Device and Quality Management System after successfully completing the audit through Germany-based notified body MDC. This ISO certification indicates [...]

Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects

By |January 30th, 2023|Categories: biomarkers, diagnose disease, extracellular vesicle, microRNA, platelet-associated miRNAs, smallRNA, thrombomiR, treatment monitoring|Tags: , , , , , , , , |

We want to draw your attention to our most recent publication where we investigated platelet-enriched miRNAs (thrombomiRs) as suitable candidates for monitoring antiplatelet therapy. The study provides evidence that thrombomiRs are promising [...]

Biogenity Joins Forces with TAmiRNA

By |January 17th, 2023|Categories: biomarkers, diagnose disease, microRNA, NGS, smallRNA, treatment monitoring|Tags: , , , , , , , |

The collaboration between Biogenity and TAmiRNA is a big step towards further enabling our clients to identify new biomarkers that can be used to diagnose disease, monitor treatment response, and predict patient [...]

Comments Off on Biogenity Joins Forces with TAmiRNA
Go to Top